Loading…
Loading…
EQUITY / NASDAQ · XNCM
Daré Bioscience, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗0.8533 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 0.8533 USD · Volume 276,434
21 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Revenue | 187,546 USD | — | — |
| Operating profit | -2,967,980 USD | -3,827,800 USD | — |
| Net income | -2,982,773 USD | -4,016,483 USD | — |
| Cash and cash equivalents | 12,617,594 USD | 5,035,006 USD | +150.60% |
| Total liabilities | 22,930,209 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 12,617,594 USD | — | — | 24,711,356 USD | 24,711,356 USD | 23,075,261 USD | — | 5,035,006 USD |
| Net incomeIncome statement | -2,982,773 USD | -5,982,662 USD | -2,999,889 USD | — | -13,399,274 USD | -3,562,766 USD | -11,957,556 USD | -4,016,483 USD |
| Operating profitIncome statement | -2,967,980 USD | -5,966,878 USD | — | — | -13,552,334 USD | -3,672,148 USD | -12,081,066 USD | -3,827,800 USD |
| RevenueIncome statement | 187,546 USD | 340,001 USD | — | — | 1,030,193 USD | 2,262 USD | 6,517 USD | — |
| Total assetsBalance sheet | 22,370,109 USD | — | — | 32,474,563 USD | 32,474,563 USD | 30,748,574 USD | — | — |
| Total equityBalance sheet | -560,100 USD | — | 734,451 USD | 2,842,634 USD | 2,842,634 USD | 2,857,903 USD | — | -12,733,260 USD |
| Total liabilitiesBalance sheet | 22,930,209 USD | — | — | 29,631,929 USD | 29,631,929 USD | 27,890,671 USD | — | — |
| Capital expendituresCash flow statement | — | 80,586 USD | — | — | 385,278 USD | — | 178,637 USD | — |
| Financing cash flowCash flow statement | — | 235,747 USD | — | — | 19,277,144 USD | — | 18,853,015 USD | — |
| Investing cash flowCash flow statement | — | -80,586 USD | — | — | -385,278 USD | — | -178,637 USD | — |
| Operating cash flowCash flow statement | — | -12,295,690 USD | — | — | -9,885,870 USD | — | -11,330,134 USD | — |
| Report source | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 08/13/2026 | Open report ↗ Published: 03/26/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 08/13/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.